Annexon, Inc.

NASDAQ: ANNX · Healthcare · Biotechnology

PublicHQ Brisbane, CA · San MateoCIK 0001528115Reports USD

#1 of 1,417 Healthcare companies by revenue

EA Score

——

FH 44DQ —GM —SS 57

v0.1 · 35/100 weight · pillars only

↑ market scale, balance-sheet leverage · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$206.7M

Employees

as of 2026-08-11

Market cap

$883.1M

as of 2026-08-11

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$206.7M-$206.7M2025

Operating income-$216.4M-$216.4M2025

Total assets$277.6M$277.6M2025

Liabilities$65.9M$65.9M2025

Equity$211.6M$211.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Annexon, Inc.’s financial profile?

Annexon, Inc. earned -$206.7M in FY2025 net income.

Peers · Healthcare

Alto Neuroscience, Inc.——Lumexa Imaging Holdings, Inc. Common Stock——Sana Biotechnology, Inc.——Faeth Therapeutics, Inc.——Aura Biosciences, Inc.——Climb Bio, Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEODouglas E. Love

SectorHealthcare

IndustryBiotechnology

HeadquartersBrisbane, CA

ExchangeNASDAQ: ANNX

Employees93

IPO date2020-07-24

Latest filings

10-Q2026-08-12 8-K2026-08-12 8-K2026-08-10 8-K2026-08-06 8-K2026-07-30 8-K2026-06-12 8-K2026-05-07 10-Q2026-05-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.